Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (211-220 of 277) with videos related to

Pageof 28
Sort By:
The Journal of Clinical Investigation|February 13, 2019
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancersTina Gruosso, Mathieu Gigoux, Venkata Satya Kumar Manem, et al.
Breast Cancer Research : BCR|December 28, 2019
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancerIris Nederlof, Davide De Bortoli, Yacine Bareche, et al.
Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.
The Lancet. Digital Health|December 11, 2025
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancerYoni Schirris, Rosie Voorthuis, Mark Opdam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant ChemotherapyMiguel Martín, Rachel Yoder, Roberto Salgado, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
The Journal of Pathology|April 9, 2015
Uncovering the genomic heterogeneity of multifocal breast cancerChristine Desmedt, Debora Fumagalli, Elisabetta Pietri, et al.
Future Oncology (London, England)|October 8, 2025
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Nature Medicine|January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
Pageof 28

Showing results (211-220 of 277) with videos related to

Sort By:
Pageof 28
The Journal of Clinical Investigation|February 13, 2019
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancersTina Gruosso, Mathieu Gigoux, Venkata Satya Kumar Manem, et al.
Breast Cancer Research : BCR|December 28, 2019
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancerIris Nederlof, Davide De Bortoli, Yacine Bareche, et al.
Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.
The Lancet. Digital Health|December 11, 2025
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancerYoni Schirris, Rosie Voorthuis, Mark Opdam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant ChemotherapyMiguel Martín, Rachel Yoder, Roberto Salgado, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
The Journal of Pathology|April 9, 2015
Uncovering the genomic heterogeneity of multifocal breast cancerChristine Desmedt, Debora Fumagalli, Elisabetta Pietri, et al.
Future Oncology (London, England)|October 8, 2025
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Nature Medicine|January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
Pageof 28